The purpose of this study is to see if an investigational drug called pazopanib can improve nosebleeds and anemia in patients with hereditary hemorrhagic telangiectasia.
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Raj Kasthuri
Medicine-Hematology
Clinical or Medical
Interventional
Blood Conditions
Rare Diseases
22-1782
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
